Med Tech-related technology assessments from NICE in October 2024

The National Institute for Health and Care Excellence (NICE) Diagnostic Guidance (DG) program focuses on evaluating innovative medical diagnostic technologies to ensure that the NHS can adopt clinically and cost-effective technologies rapidly and consistently.

In October 2024, NICE published two new Diagnostic Guidance.

The following conclusions were made in DG on heart failure algorithms for remote monitoring in people with cardiac implantable electronic devices (CIEDs):

• Two technologies received positive recommendations - HeartLogic and TriageHF were recommended as options for algorithm-based remote monitoring in people with CIEDs who have heart failure. The technologies should be used as part of a specialist multidisciplinary heart failure service with alerts reviewed and acted on by specialist healthcare professionals;
• In the following cases, technologies were only recommended in the context of research:
  • For people with heart failure, more research is needed on HeartInsight before it can be routinely used in the NHS;
  • For people at risk of developing heart failure, more research is needed on HeartInsight, HeartLogic, and TriageHF before they can be routinely used in the NHS;
• One technology (CorVue) was not recommended.

The following conclusions were made in DG on digital technologies for assessing attention deficit hyperactivity disorder (ADHD):

• One technology – QbTest - was recommended as an option to help diagnose ADHD in people aged 6 to 17 years. It should only be used with standard clinical assessment by a healthcare professional;
• In other cases, technologies can only be used in research:
  • For people with suspected ADHD, more research is needed on using the following digital technologies to help diagnose ADHD: QbTest in people 18 years and over, EFSim Test, EFSim Test Web Version, Nesplora Attention Adults Aquarium, Nesplora Attention Kids Aula, QbCheck;
  • For people with ADHD, more research is needed on using the following digital technologies to evaluate response to treatment: QbTest, EFSim Test, EFSim Test Web Version, Nesplora Attention Adults Aquarium, Nesplora Attention Kids Aula, and QbCheck.

Furthermore, in October 2024, NICE updated one clinical guideline on acute kidney injury prevention, detection, and management.

See the full details here.

This news is just one of about 300 market access news collected by our team in the premium subscription service Market Access Monitor every week from more than 80 organizations. Access our paid service to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). Access is organized as an online Database and email alert formats. Contact us to get a free, three-month, no-obligation trial.